Close Menu

NEW YORK – AstraZeneca and Merck's olaparib (Lynparza) received approval on Thursday from China's National Medical Products Administration for newly diagnosed advanced ovarian cancer patients whose tumors have somatic or germline BRCA1/2 mutations. 

The drug is intended to be used as a first-line maintenance treatment,which aims to prolong remission and reduce the risk of disease progression in this subset of patients. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jan
28

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.